These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 6418898)

  • 1. Failure of activated prothrombin complex concentrates in a hemophiliac with an anti-factor VIII antibody.
    Blatt PM; White GC; McMillan CW; Webster WP
    JAMA; 1984 Jan; 251(1):67. PubMed ID: 6418898
    [No Abstract]   [Full Text] [Related]  

  • 2. There is no correlation between vitamin K dependent coagulant content and clinical effectiveness of activated and standard factor IX complex concentrates.
    Aronson DL
    Prog Clin Biol Res; 1984; 150():243-50. PubMed ID: 6379676
    [No Abstract]   [Full Text] [Related]  

  • 3. [Inhibitor hemophilia in oral surgery].
    Schulz S
    Zahn Mund Kieferheilkd Zentralbl; 1984; 72(8):824-8. PubMed ID: 6240865
    [No Abstract]   [Full Text] [Related]  

  • 4. [Clinical effects of FEIBA on hemophilia patients with inhibitors to factor VIII or IX].
    Iizuka A; Kuwashima M; Nagao T
    Nihon Ketsueki Gakkai Zasshi; 1982 Sep; 45(5):987-92. PubMed ID: 6818811
    [No Abstract]   [Full Text] [Related]  

  • 5. Conjectures on factor VIII bypassing activity.
    Aronson DL
    Prog Clin Biol Res; 1981; 72():103-21. PubMed ID: 6977778
    [No Abstract]   [Full Text] [Related]  

  • 6. Laboratory evidence of DIC under FEIBA treatment of a hemophilic patient with intracranial bleeding and high titre factor VIII inhibitor.
    Fukui H; Fujimura Y; Takahashi Y; Mikami S; Yoshioka A
    Thromb Res; 1981 Apr 1-15; 22(1-2):177-84. PubMed ID: 6794176
    [No Abstract]   [Full Text] [Related]  

  • 7. [Articular and muscular hemorrhages in hemophilia A with anti-factor VIII antibodies. Treatment with selected batches of PPSB (factor IX concentrate)].
    Verroust F; Moussard C; Allain JP
    Presse Med; 1985 May; 14(19):1073-6. PubMed ID: 3158962
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Treatment of hemophiliacs with inhibitors].
    Fujimaki M
    Rinsho Ketsueki; 1985 Jul; 26(7):1059-68. PubMed ID: 3932719
    [No Abstract]   [Full Text] [Related]  

  • 9. Anti-factor VIII anamnesis after factor IX complex.
    Palascak JE; Shapiro SR
    N Engl J Med; 1977 Dec; 297(25):1403. PubMed ID: 927458
    [No Abstract]   [Full Text] [Related]  

  • 10. Hemophiliacs with inhibitors: therapeutic options.
    Roberts HR
    N Engl J Med; 1981 Sep; 305(13):757-8. PubMed ID: 6790992
    [No Abstract]   [Full Text] [Related]  

  • 11. Effects of low-dose 'factor VIII inhibitor bypassing activity (FEIBA)' in resistant haemophilia.
    Zwahlen H; Beck EA
    Acta Haematol; 1980; 64(1):12-7. PubMed ID: 6774572
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Treatment of patients with hemophilia A having antibodies to factor VIII].
    Lopaciuk S; Ziemski JM
    Acta Haematol Pol; 1979; 10(2):115-22. PubMed ID: 474044
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New activated factors IX product in haemophilia.
    Abonstam A; Aston L; Wassef M; Hamad Z
    Lancet; 1980 Dec; 2(8207):1294. PubMed ID: 6108461
    [No Abstract]   [Full Text] [Related]  

  • 14. Life-threatening sublingual hematoma in a severely hemophilic patient with factor VIII inhibitor.
    Takeuchi M; Shikimori M; Kaneda T
    J Oral Maxillofac Surg; 1986 May; 44(5):401-3. PubMed ID: 3084733
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of activated prothrombin-complex concentrate (FEIBA) on joint and muscle bleeding in patients with hemophilia A and antibodies to factor VIII. A double-blind clinical trial.
    Sjamsoedin LJ; Heijnen L; Mauser-Bunschoten EP; van Geijlswijk JL; van Houwelingen H; van Asten P; Sixma JJ
    N Engl J Med; 1981 Sep; 305(13):717-21. PubMed ID: 6790990
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Inhibitors and "bypass" therapy in hemophilia].
    Fukutake K; Fukutake K
    Nihon Rinsho; 1981; 39(12):3688-99. PubMed ID: 6803034
    [No Abstract]   [Full Text] [Related]  

  • 17. [Therapy of immuninhibitor hemophilia A with FEIBA plasma fraction].
    István L; Bariska I; Marton E
    Orv Hetil; 1980 Dec; 121(51):3131-5. PubMed ID: 6784062
    [No Abstract]   [Full Text] [Related]  

  • 18. The past and future of haemophilia: diagnosis, treatments, and its complications.
    Peyvandi F; Garagiola I; Young G
    Lancet; 2016 Jul; 388(10040):187-97. PubMed ID: 26897598
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Failure of factor VIII inhibitor bypassing activity (Feiba) to secure haemostasis in haemophilic patients with antibodies.
    Parry DH; Bloom AL
    J Clin Pathol; 1978 Nov; 31(11):1102-5. PubMed ID: 739057
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The optimal treatment for haemophiliacs who have developed factor VIII or -IX antibodies.
    Engelfriet CP; Reesink HW; Mannucci PM; Gringeri A; Ingerslev J; Brettler DB; Mauser-Bunschoten EP; Negrier C; Berntorp E; Smith OP; Shapiro AD
    Vox Sang; 2000; 78(4):256-61. PubMed ID: 10970234
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.